Study on Effects of GLP-1 and GIPGLP-1 Analog Treatments on Diet, Metabolism, and Behavior in Adults with Overweight or Obesity

What this Trial Is About

Researchers are studying the effects of GLP-1 and GIPGLP-1 analogue medications on both metabolic and behavioral factors in people with excess body weight. This research focuses on how these treatments influence diet quality and quantity, weight loss, body composition, and biochemical markers. The study also looks at appetite regulation, risk of malnutrition, muscle loss, and any side effects that may occur during treatment for overweight and obesity. The study involves participants who are starting treatment with GLP-1 or GIPGLP-1 analogues and includes four visits to a clinic over one year before treatment and at 3, 6, and 12 months after starting. Researchers will track changes in weight, lean body mass, fat mass, blood sugar control, lipid levels, liver and kidney function, diet quality, eating behaviors, food preferences, physical activity, and muscle strength. Participants will be assessed through visits that include measurements of body weight and composition, blood tests for metabolic markers, questionnaires about diet and eating behavior, and physical activity monitoring. The main outcome is the change in body weight after 12 months. The study will also monitor safety and adverse events throughout the year. Total participation lasts one year with regular follow-ups at specified intervals.

The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight